TY - JOUR
T1 - COVID-19 in pediatric kidney transplantation
T2 - a follow-up report of the Improving Renal Outcomes Collaborative
AU - Varnell, Charles
AU - Harshman, Lyndsay A.
AU - Liu, Chunyan
AU - Smith, Laurie
AU - Al-Akash, Samhar
AU - Barletta, Gina Marie
AU - Brakeman, Paul
AU - Chaudhuri, Abanti
AU - Fadakar, Paul
AU - Galea, Lauren
AU - Garro, Rouba
AU - Gluck, Caroline
AU - Kershaw, David B.
AU - Matossian, Debora
AU - Patel, Hiren P.
AU - Peterson, Caitlin
AU - Pruette, Cozumel
AU - Ranabothu, Saritha
AU - Rodig, Nancy
AU - Singer, Pamela
AU - Sebestyen VanSickle, Judith
AU - Weng, Patricia L.
AU - Danziger-Isakov, Lara
AU - Seifert, Michael E.
AU - Hooper, David K.
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to International Pediatric Nephrology Association.
PY - 2023/2
Y1 - 2023/2
N2 - Background: We report follow-up data from an ongoing prospective cohort study of COVID-19 in pediatric kidney transplantation through the Improving Renal Outcomes Collaborative (IROC). Methods: Patient-level data from the IROC registry were combined with testing, indication, and outcomes data collected to describe the epidemiology of COVID testing, treatment, and clinical outcomes; determine the incidence of a positive COVID-19 test; describe rates of COVID-19 testing; and assess for clinical predictors of a positive COVID-19 test. Results: From September 2020 to February 2021, 21 centers that care for 2690 patients submitted data from 648 COVID-19 tests on 465 patients. Most patients required supportive care only and were treated as outpatients, 16% experienced inpatient care, and 5% experienced intensive care. Allograft complications were rare, with acute kidney injury most common (7%). There was 1 case of respiratory failure and 1 death attributed to COVID-19. Twelve centers that care for 1730 patients submitted complete testing data on 351 patients. The incidence of COVID-19 among patients at these centers was 4%, whereas the incidence among tested patients was 19%. Risk factors to predict a positive COVID-19 test included age > 12 years, symptoms consistent with COVID-19, and close contact with a confirmed case of COVID-19. Conclusions: Despite the increase in testing and positive tests over this study period, the incidence of allograft loss or death related to COVID-19 remained extremely low, with allograft loss or death each occurring in < 1% of COVID-19-positive patients and in less than < 0.1% of all transplant patients within the IROC cohort. Graphical abstract: A higher resolution version of the Graphical abstract is available as Supplementary information [Figure not available: see fulltext.].
AB - Background: We report follow-up data from an ongoing prospective cohort study of COVID-19 in pediatric kidney transplantation through the Improving Renal Outcomes Collaborative (IROC). Methods: Patient-level data from the IROC registry were combined with testing, indication, and outcomes data collected to describe the epidemiology of COVID testing, treatment, and clinical outcomes; determine the incidence of a positive COVID-19 test; describe rates of COVID-19 testing; and assess for clinical predictors of a positive COVID-19 test. Results: From September 2020 to February 2021, 21 centers that care for 2690 patients submitted data from 648 COVID-19 tests on 465 patients. Most patients required supportive care only and were treated as outpatients, 16% experienced inpatient care, and 5% experienced intensive care. Allograft complications were rare, with acute kidney injury most common (7%). There was 1 case of respiratory failure and 1 death attributed to COVID-19. Twelve centers that care for 1730 patients submitted complete testing data on 351 patients. The incidence of COVID-19 among patients at these centers was 4%, whereas the incidence among tested patients was 19%. Risk factors to predict a positive COVID-19 test included age > 12 years, symptoms consistent with COVID-19, and close contact with a confirmed case of COVID-19. Conclusions: Despite the increase in testing and positive tests over this study period, the incidence of allograft loss or death related to COVID-19 remained extremely low, with allograft loss or death each occurring in < 1% of COVID-19-positive patients and in less than < 0.1% of all transplant patients within the IROC cohort. Graphical abstract: A higher resolution version of the Graphical abstract is available as Supplementary information [Figure not available: see fulltext.].
KW - COVID-19
KW - Improving Renal Outcomes Collaborative
KW - Kidney transplant
UR - http://www.scopus.com/inward/record.url?scp=85129898389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129898389&partnerID=8YFLogxK
U2 - 10.1007/s00467-022-05570-w
DO - 10.1007/s00467-022-05570-w
M3 - Article
C2 - 35538239
AN - SCOPUS:85129898389
SN - 0931-041X
VL - 38
SP - 537
EP - 547
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 2
ER -